Suresh S. Ramalingam
Lung cancer medical oncologist who leads Winship Cancer Institute of Emory University and led the FLAURA trial of osimertinib.
Overview
Suresh S. Ramalingam is Executive Director of Winship Cancer Institute of Emory University, Georgia's NCI-designated comprehensive cancer centre. A thoracic medical oncologist, he was a principal investigator of the FLAURA trial establishing osimertinib as first-line therapy for EGFR-mutated non-small cell lung cancer, and has led numerous national lung cancer trials through ECOG-ACRIN.
| Title | Journal | Year |
|---|---|---|
| Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | New England Journal of Medicine | 2020 |
Pages like this
not linked directly; found by shared links- PersonMartin Schuler
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tags leadership, clinician-scientist, lung cancer.
- PersonCaicun Zhou
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tags leadership, clinician-scientist, lung cancer.
- PersonShun Lu
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tags clinician-scientist, lung cancer, targeted therapy.
- PersonKaren Kelly
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tags leadership, clinician-scientist, lung cancer.
- PersonAlexis Cortot
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tags leadership, clinician-scientist, lung cancer.
- PersonNobuyuki Yamamoto
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tags leadership, clinician-scientist, lung cancer.
- PersonAlfredo Addeo
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tags leadership, clinician-scientist, lung cancer.
- PersonDavid Planchard
Shares Non-small-cell lung cancer and the tags clinician-scientist, lung cancer, targeted therapy.